SLIT and NTRK like family member 1Genealiases: LRRC12 · TTM
Q-omics provides the consensus-scored SLITRK1 profile across patient tissues and cancer cell-line models. SLITRK1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLITRK1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SLITRK1 RNA expression shows 13,181 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where SLITRK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLITRK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLITRK1 survival associations across molecular data types. SLITRK1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLITRK1 RNA expression–survival associations across cancer types. High SLITRK1 expression shows unfavorable associations in KIRC, KIRP, LIHC and BLCA, but favorable associations in LGG and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLITRK1 RNA expression.
This table summarizes SLITRK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLITRK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLITRK1 shows lower tumor expression in KIRC, COAD, KICH, THCA, READ and PRAD. The KIRC box plot shows higher SLITRK1 RNA expression in normal versus tumor tissue (log2 FC = −0.058, t-test p < 0.001).
This table shows molecular features associated with SLITRK1 in patient tissues and cancer cell lines. In patient samples, SLITRK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLITRK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
